Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07531095 · ClinicalTrials.gov registry record · Phase 1
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
A Phase 1 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT07531095 is a Phase 1 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 160 participants.
The verdict
NCT07531095, a Phase 1 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.
Interventions
- DRUG ZL-1310
- DRUG Durvalumab
- DRUG Tarlatamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-04-21 |
| Est. Completion | 2031-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07531095
The ClinicalTrials.gov registry entry for NCT07531095 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ZL-1310 is the first listed.
NCT07531095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07531095 about?
NCT07531095 is a clinical study titled "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)". The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.
What is the current status of trial NCT07531095?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2026-04-21. Estimated completion is 2031-05-21.
What interventions are being tested in trial NCT07531095?
The interventions under investigation include: ZL-1310 (DRUG), Durvalumab (DRUG), Tarlatamab (DRUG).
Who is sponsoring clinical trial NCT07531095?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.